UNITED STATES


		OMB APPROVAL
	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549	OMB Number: 3235-0060 Expires: March 31, 2014 Estimated average burden hours per response……………5.00
	FORM 8-K
	CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

SECURITIES AND EXCHANGE COMMISSION



February 14, 2012		000-30237
Date of Report (Date of earliest event reported)		Commission File Number

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

December 8, 2011		000-30237
Date of Report (Date of earliest event reported)		Commission File Number

REGENECA, INC.

(Exact name of registrant as specified in its charter)



Nevada		88-0467241
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification Number)

1 Technology, Suite C515 Irvine, CA 92618
(Address of Principal Executive Offices) (Zip Code)

(949) 887-6890
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 5.02	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective as of ~~December~~February 814, ~~2011~~2012, ~~Shirish~~Daniel ~~Phulgaonkar~~R. Kerker resigned as the Chief ~~Scientific~~Financial Officer/Treasurer of the Company. ~~The~~ ~~Company~~There ~~does~~are ~~not~~no ~~intend~~disagreements tobetween ~~appoint another individual to~~ the ~~Chief~~Company ~~Scientific~~and ~~Officer position at this time. Pursuant to his employment agreement,~~ Mr. ~~Phulgaonkar was primarily responsible for production of RegenErectTM~~Kerker, ~~the~~and ~~Company’s~~his ~~male enhancement product. Management has concluded that this~~ resignation ~~will~~did ~~affect~~not ~~its~~state ~~ability~~any toreason ~~replenish~~for ~~its~~his ~~inventory of RegenErectTM~~resignation. ~~Management~~ ~~is uncertain of when and if the Company will be able to produce further inventory of RegenErectTM at this time.~~

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	REGENECA, INC.
December 12, 2011		/s/ MATTHEW NICOSIA
February 22, 2012		/s/ Matthew Nicosia
	Name:	Matthew Nicosia
	Title:	CEO, President and Chairman

Filing Compare · Regeneca, Inc.